Leap Therapeutics Shares Surge Following $59M Crypto Deal Led by Winklevoss

Shares of Leap Therapeutics (LPTX) surged 25% after the microcap cancer drug developer announced a $58.9 million private investment led by Winklevoss Capital to launch a crypto treasury strategy.

The private placement includes common shares and warrants priced at $0.61439 per unit. As part of the deal, Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will secure two seats on Leap’s board.

Leap, known for its immuno-oncology therapies, said a portion of the proceeds will be used to purchase cryptocurrency to hold on its balance sheet, while the remainder will support ongoing clinical development of its drug candidates. Specific cryptocurrencies to be acquired were not disclosed.

This move positions Leap among a growing cohort of public companies using crypto as a treasury reserve. The company stated that additional details on its digital asset strategy will be shared in the near future.

Shares were up 25% in Monday morning trading.

  • Related Posts

    Binance expands its platform with a prediction market offering for millions of users.

    Binance has added a prediction markets feature to its Binance Wallet, enabling users to trade on real-world event outcomes directly within the app. The integration links Binance Wallet to Predict.fun,…

    Continue reading
    Bhutan has reportedly divested 70% of its Bitcoin over the past 18 months and may have paused or ended BTC mining.

    Bhutan is steadily exiting one of the most closely watched sovereign bitcoin strategies, continuing a measured reduction in its holdings. The kingdom’s reserves have declined from roughly 13,000 BTC in…

    Continue reading